Hemispherx Biopharma, Inc. (HEB) Reports Q2 Loss of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HEB Hot Sheet
Price: $1.80 --0%
Financial Fact:
Total costs and expenses: 2.83M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total costs and expenses: 2.83M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Hemispherx Biopharma, Inc. (NYSE: HEB) reported Q2 EPS of ($0.02), versus ($0.02) reported last year.
For earnings history and earnings-related data on Hemispherx Biopharma, Inc. (HEB) click here.
For earnings history and earnings-related data on Hemispherx Biopharma, Inc. (HEB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
- AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
